Unveiling the future of cell and gene therapies in the UK

In recent years, cell and gene therapies have been advancing at lightning speed, offering new hope to…

New Alzheimer’s treatment ‘lecanemab’ approved for use in the US

LifeArc played an instrumental role in the drug’s development through our antibody humanisation work.

Catriona Crombie talks to Rare Revolution about LifeArc’s investment of more than £100 million into rare disease research by 2030

Catriona discusses why LifeArc is well placed to help overcome some of the obstacles in rare disease research

How LifeArc’s Neurodegeneration Translational Challenge is leading the charge against Motor Neurone Disease

June 21st is Global MND Awareness Day, a day to raise worldwide awareness of MND (Motor Neurone Disease) and to stand in solidarity with the MND/ALS community.

Meet our industrial placement students – class of 2023

Find out what this year's cohort of industrial placement students gained from the experience.

Translational research into children’s rare diseases enters 5th year of collaborative funding

Accelerating research that will have a significant impact on the treatment of children and young people

Talking to FLIER future leaders about learning from COVID-19 and the power of collaboration

The Future Leaders in Innovation Enterprise and Research is a two-year programme for emerging leaders in science, technology and medicine.

Highlights from Illumina for Startups Summit 2023

Key takeaways from the summit for entrepreneurs, founders, investors and industry leaders from around the world.

International Women’s Day 2023

Tips on career advancement, from some of LifeArc’s incredible women